NexImmune (STU:7370) Beta: 0.5023 (As of Jul. 12, 2026)


STU:7370 NexImmune Inc STU:7370
33 GF Score
Price €4.55
View Full Analysis

What is NexImmune Beta?

NexImmune STU:7370 33 Beta is 0.5023 as of Jul. 12, 2026. GuruFocus rates STU:7370 with a GF Score™ of 33/100.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-12), NexImmune's Beta is 0.5023.


NexImmune  (STU:7370) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


NexImmune Beta Related Terms


NexImmune Beta Historical Data

* Premium members only.

The historical data trend for NexImmune's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NexImmune Beta Chart

NexImmune Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

NexImmune Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 2.03 2.08

STU:7370 vs PPCBD, ENDV, XSNX: Beta Comparison

For the Biotechnology subindustry, NexImmune's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NexImmune Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NexImmune's Beta distribution charts can be found below:

* The bar in red indicates where NexImmune's Beta falls into.


STU:7370
33GF Score
NexImmune Inc STU:7370
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NexImmune Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.5023 mean?
NexImmune (STU:7370) has a Beta of 0.5023 as of Jul. 12, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for NexImmune and its competitors.
Is NexImmune's Beta too high?
NexImmune's current Beta is 0.5023. Overall, NexImmune has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does NexImmune's Beta compare to PPCBD and ENDV?
NexImmune's Beta of 0.5023 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for NexImmune and its competitors. NexImmune's current Beta is 0.5023. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexImmune stock overvalued right now?
NexImmune (STU:7370) has a current Beta of 0.5023. The current Beta is 0.5023. NexImmune's overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For NexImmune (STU:7370), the current Beta is 0.5023 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NexImmune Business Description

Address 9119 Gaither Road, Gaithersburg, MD, USA, 20877
NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
33GF Score

Get the complete analysis for STU:7370

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.55
Price